Coagulopathy in Children

Status: draft · Last updated 2026-11-03 · By Jason S. Hauptman, MD, PhD (AI-assisted)

Read in the interactive book →

High-yield points

  • Neonates are different, not defective:
    • Vitamin K-dependent factors are 40–60% of adult levels, and the PT and aPTT run long.
    • Most values reach near adult by 6 months.
    • Use age- and analyzer-specific ranges .
  • Before blaming the patient, exclude the sample: a difficult draw, an under-filled tube or a high hematocrit .
  • An isolated long aPTT with no bleeding history may be factor XII deficiency. Mucosal bleeding with normal labs suggests VWD .
  • An infant with ICH and a long PT: think late VKDB. Ask about vitamin K .
  • Reversal:
    • Warfarin: vitamin K + 4F-PCC.
    • Heparin: protamine 1 mg/100 U.
    • Enoxaparin: protamine 1 mg/mg within 8 hours.
    • Dabigatran: idarucizumab.
    • Xa inhibitors: PCC or andexanet.
    • Antiplatelets: platelets only if operating .
  • Intraoperative bleeding:
    • Run a goal-directed protocol: FFP 15–20 mL/kg, platelets 10 mL/kg (keep above 50,000), and early fibrinogen replacement.
    • Give TXA for major cranial surgery.
    • Keep rFVIIa as a last resort .

Landmark papers

  • Goobie et al., Anesthesiology 2011: a double-blind, placebo-controlled trial in 43 children having craniosynostosis surgery. TXA cut blood loss (65 vs 119 mL/kg) and transfusion (33 vs 56 mL/kg) .
  • PATCH (Baharoglu et al., Lancet 2016): a randomized trial in adults. Platelet transfusion for antiplatelet-associated ICH without surgery increased death or dependence (adjusted OR 2.05) .
  • NCS/SCCM guideline (Frontera et al., Crit Care Med 2016): an adult guideline for reversal of antithrombotics in intracranial hemorrhage, the source of the reversal doses in this topic .

Pediatric neurosurgical bleeding is unforgiving: blood volumes are small, the skull is closed, and an inherited bleeding disorder may first show itself in the operating room. Neonates and infants are at highest risk. Their hemostatic system is immature, and an underlying inherited disorder may not yet have been diagnosed . Read infant coagulation tests against age-appropriate norms. Know the common anticoagulants and their antidotes, and have a plan for intraoperative coagulopathy.

Normal physiology: developmental hemostasis

Lab values: normal vs. abnormal

Congenital coagulopathies

Acquired coagulopathies

Common medications and their reversal

The doses below come from the Neurocritical Care Society/SCCM guideline for antithrombotic-associated intracranial hemorrhage. It is an adult guideline, so confirm pediatric weight-based dosing with pharmacy and hematology .

Emergent management of coagulopathy during surgery

Related topics

References

  1. Erdoes G, Goobie SM, Haas T, et al. Perioperative considerations in the paediatric patient with congenital and acquired coagulopathy. BJA Open 2024;12:100310. doi:10.1016/j.bjao.2024.100310. PMID 39376894. verified
  2. Gorio C, Molinari AC, Martini T, et al. Hemostasis laboratory diagnostics in newborns. J Clin Med 2025;14(14):5068. doi:10.3390/jcm14145068. PMID 40725765. verified
  3. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70(1):165–172. PMID 3593964. verified
  4. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72(5):1651–1657. PMID 3179444. verified
  5. Monagle P, Barnes C, Ignjatovic V, et al. Developmental haemostasis: impact for clinical haemostasis laboratories. Thromb Haemost 2006;95(2):362–372. doi:10.1160/TH05-01-0047. PMID 16493500. verified
  6. Talving P, Lustenberger T, Lam L, et al. Coagulopathy after isolated severe traumatic brain injury in children. J Trauma 2011;71(5):1205–1210. doi:10.1097/TA.0b013e31820d151d. PMID 21427617. verified
  7. Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046. PMID 32744769. verified
  8. Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021;5(1):301–325. doi:10.1182/bloodadvances.2020003264. PMID 33570647. verified
  9. Araki S, Shirahata A. Vitamin K deficiency bleeding in infancy. Nutrients 2020;12(3):780. doi:10.3390/nu12030780. PMID 32187975. verified
  10. Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the Neurocritical Care Society and the Society of Critical Care Medicine. Crit Care Med 2016;44(12):2251–2257. doi:10.1097/CCM.0000000000002057. PMID 27858808. verified
  11. Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020;7(1):e18–e27. doi:10.1016/S2352-3026(19)30219-430219-4). PMID 31699660. verified
  12. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal: full cohort analysis. N Engl J Med 2017;377(5):431–441. doi:10.1056/NEJMoa1707278. PMID 28693366. verified
  13. Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019;380(14):1326–1335. doi:10.1056/NEJMoa1814051. PMID 30730782. verified
  14. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet 2016;387(10038):2605–2613. doi:10.1016/S0140-6736(16)30392-030392-0). PMID 27178479. verified
  15. Goobie SM, Meier PM, Pereira LM, et al. Efficacy of tranexamic acid in pediatric craniosynostosis surgery: a double-blind, placebo-controlled trial. Anesthesiology 2011;114(4):862–871. doi:10.1097/ALN.0b013e318210fd8f. PMID 21364458. verified
  16. Lutmer JE, Mpody C, Sribnick EA, et al. Prothrombin complex concentrate utilization in children's hospitals. J Pediatr Intensive Care 2023;12(3):219–227. doi:10.1055/s-0041-1731686. PMID 37565019. verified
  17. McQuilten ZK, Barnes C, Zatta A, et al. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 2012;129(6):e1533–e1540. doi:10.1542/peds.2011-2561. PMID 22641758. verified

Verification (2026-11-03): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. PubMed lists no DOI for references 3 and 4. Numbers were checked against PubMed abstracts and, where noted, full texts:

Caveats: reference 10 is an adult guideline, and its fixed adult doses (for example, vitamin K 10 mg and idarucizumab 5 g) are not pediatric doses. References 12–14 studied adults. No pediatric dose for vitamin K, PCC or andexanet is given here, because none was verified. Specific neonatal PT/aPTT numbers are omitted on purpose, because ranges depend on the analyzer . The original Andrew tables could not be accessed. The FFP and platelet volumes in reference 1 come from a viscoelastic-guided cardiac algorithm and are standard practice, not trial-derived thresholds for neurosurgery.